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SINTESIS, PENCIRIAN DAN KAJIAN ANTI-PROLIFERASI TERBITAN  
BENZIMIDAZOL 
 
ABSTRAK 
 
Empat jenis sebatian organik telah disintesis dan dicirikan. Sintesis 
sebatian ini melibatkan tindak balas pembenzilan, penambahan penyingkiran dan 
pensiklikan. Struktur sebatian yang disintesis dipastikan secara takat lebur, 
spektroskopi FTIR, HRMS, NMR 1D dan 2D dan kristalografi sinar-X. Sebatian 
jenis pertama adalah 2-benziloksi-3-metoksibenzaldehid 75, yang telah disintesis 
dengan tindak balas o-vanilin dengan benzil bromida dalam aseton sebagai pelarut 
dan K2CO3 sebagai bes dengan kehadiran tetra-n-butilammonium iodida (TBAI) 
sebagai mangkin. Sebatian jenis kedua yang dikaji adalah 2-amino-N-benzilidin 
benzenamina 76 dan 82, yang disintesis dengan tindak balas o-fenilenadiamina 
dengan o-vanilin atau 75 dalam diklorometana dalam keadaan sejuk. Kedua-dua 
eksperimen NMR 1H–1H COSY dan HMBC dijalankan untuk mengesahkan 
kedudukan jalur sebatian dalam CDCl3, CD2Cl2 dan aseton-d6. Sebahagian kesan 
daripada gelang enam- dan lima- illusory terhasil daripada pembentukan 
intramolekul ikatan hidrogen antara N–H dalam gelang amino dan atom N dalam 
ikatan N=C–H dan O–H dengan atom N pada N=C–H pada 76 atau antara N–H 
dalam gelang amino dan atom N dalam ikatan N=C–H dan ikatan C–H metina pada 
82 dengan atom oksigen dalam gelang benziloksi. Struktur kristal kedua 76 dan 82 
disahkan dengan menggunakan analisis kristalografi sinar-X. Sebatian jenis ketiga 
yang dikaji adalah bes bis-Schiff 79, 80 and 81, yang dihasilkan dengan tindak balas 
antara o-vanillin dengan o-, m- dan p-fenilenadiamina, masing-masing, oleh 
mekanisme tetrahedra atau mekanisme penambahan penyingkiran. Struktur kristal 
xxxiv 
 
bes bis-Schiff disahkan gelang enam- illusory, yang dihasilkan daripada 
pembentukan intramolekul ikatan hydrogen antara ikatan N=C–H dan kumpulan O–
H pada gelang tritertukarganti yang disahkan dengan menggunakan analisis 
kristalografi sinar-X. Sebatian jenis keempat adalah benzimidazol 77, 78, 83 dan 84, 
yang telah dihasilkan daripada amino benzenamina 76 and 82, masing-masing, dalam 
media berakues atau berbes dengan mekanisme penambahan penyingkiran diikuti 
oleh mekanisme pensiklikan. Eksperimen NMR 1H, 13C, 1H–1H COSY, HMQC dan 
HMBC dijalankan untuk mengesahkan kedudukan jalur pada 77, 78, 83 dan 84. 
Struktur kristal benzimidazol 77, 78 dan 83 disahkan dengan menggunakan analisis 
kristalografi sinar-X. Semua benzimidazol telah dinilaikan terhadap titisan sel kanser 
payudara MCF–7 dan titisan sel kanser kolon HCT–116 menggunakan kaedah MTT. 
Keputusan benzimidazol 84 menunjukkan aktiviti sitotoksik yang tinggi terhadap 
titisan sel MCF–7 dengan IC50 = 8.86 ± 1.10 g/mL, dan aktiviti sitotoksik yang 
sederhana terhadap titisan sel HCT–116 dengan IC50 = 24.08 ± 0.31 g/mL. 
Manakala benzimidazol 78 menunjukkan IC50 rendah bernilai 16.18 ± 3.85 g/mL 
terhadap titisan sel HCT–116. Kedua benzimidazol 77 dan 78 menunjukkan aktiviti 
sitotoksik yang sederhana terhadap titisan sel MCF–7, manakala benzimidazol 83 
tidak menunjukkan sebarang aktiviti terhadap titisan sel MCF–7 dan HCT–116. 
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SYNTHESIS, CHARACTERIZATION AND ANTI-PROLIFERATION 
STUDY OF SOME BENZIMIDAZOLE DERIVATIVES 
 
ABSTRACT 
 
Four different types of compounds were successfully synthesized and 
characterized. The syntheses of these compounds involved benzylation, addition 
elimination and cyclization reactions. The structures of the synthesized compounds 
were confirmed by melting points, FTIR, HRMS, 1D and 2D NMR spectroscopy and 
X–ray crystallography. The first type of these compounds is 2-benzyloxy-3-
methoxybenzaldehyde 75, which was synthesized by the reaction of o-vanillin with 
benzyl bromide in acetone as the solvent and K2CO3 as a base in the presence of 
tetra-n-butylammonium iodide (TBAI) as catalyst. The second type of the studied 
compounds is 2-amino-N-benzylidene benzeneamines 76 and 82, which were 
synthesized from the reaction of o-phenylenediamine with o-vanillin or 75 in 
dichloromethane at cold conditions. Both 1H–1H COSY and HMBC NMR 
experiments were performed to further confirm the assigned peaks of compounds in 
CDCl3, CD2Cl2 and acetone-d6. Some effect from those six– and five–membered 
illusory rings, which were formed from the intramolecular hydrogen bonding 
between N–H in the amino ring and the N atom in N=C–H bond and O–H with N 
atom of N=C–H of 76 or between N–H in the amino ring and the N atom in N=C–H 
bond and the bond of the methine C–H of 82 with oxygen atom in the benzyloxy 
ring. The crystal structures of both 76 and 82 confirmed the hydrogen bonds by using 
the X–ray crystallographic analysis. The third type of the studied compounds is bis-
Schiff bases 79, 80 and 81, which are formed from the reaction between o-vanillin 
with o-, m- and p-phenylenediamines, respectively, by a tetrahedral mechanism or 
xxxvi 
 
addition/elimination mechanism. The crystal structures of those bis-Schiff bases 
confirmed six–membered illusory rings, which formed from the intramolecular 
hydrogen bonding between N=C–H bonds and O–H groups of the trisubstituted rings 
by using the X–ray crystallographic analysis. The fourth type of the studied 
compounds is benzimidazoles 77, 78, 83 and 84, which are converted from amino 
benzeneamines 76 and 82, respectively, in aqua or basic media by 
addition/elimination mechanism followed by cyclization. Those benzimidazoles have 
been evaluated against both breast cancer cell line MCF–7 and colon cancer cell line 
HCT–116 using MTT assay. The results of benzimidazole 84 showed high cytotoxic 
activity against MCF–7 cell lines with IC50 = 8.86 ± 1.10 g/mL, and moderate 
cytotoxic activity against HCT–116 cell lines with IC50 = 24.08 ± 0.31 g/mL. 
Benzimidazole 78 showed the lowest IC50 value at 16.18 ± 3.85 g/mL against 
HCT–116 cell lines. Both benzimidazoles 77 and 78 showed moderate cytotoxic 
activity against MCF–7 cell lines, while benzimidazole 83 showed no cytotoxic 
effect with both MCF–7 and HCT–116 cell lines. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Schiff bases 
Schiff bases or imines are compounds formed from the condensation 
reaction between aldehydes or ketones and primary amines or amino acids in the 
presence of an acid catalyst (Figure 1.1). The product containing an azomethine, 
C=N linkage was discovered by Hugo Joseph Schiff (Layer, 1963; Cozzi, 2004). 
Many nomenclatures are used to describe the formation of Schiff bases, for example: 
aldimines, anils, benzanils and ketimines, derived from aldehydes, aniline, aromatic 
aldehydes and ketones, respectively (Layer, 1963; El–Bayoumi et al., 1971a,b). 
 
Figure 1.1: The general formula of Schiff base or imine. 
 
These compounds are ranked among the most versatile synthetic organic 
intermediates, which are important for the synthesis of biologically important 
compounds. They are widely used as medical, pharmaceutical and industrial 
materials and were reported to show a variety of biological activities including as 
antifungal (Singh and Dash, 1988; More et al., 2001), antibacterial (Baseer et al., 
2000; El-Masry et al., 2000; Kabeer et al., 2001) and anticancer (Kuz'min et al., 
2000; Desai et al., 2001), among others. They also showed moderate activity against 
Staphylococcus aureus and Bacillus subtilis (Jarrahpour et al., 2004). 
 
CHAPTER ONE                                                                     INTRODUCTION 
2 
They have also been used extensively in inorganic and coordination 
chemistry fields for the synthesis of new organometallic compounds. The imines 
formed from the reaction of the aldehydes and amines also proved to be the source of 
versatile compounds for many transition metals where they act as donor groups to 
bind the metal ions (Vigato and Tamburini, 2004). Besides that, Schiff bases are also 
used to produce new azo dyes (Jarrahpour and Zarei, 2004, Naeimi et al., 2007). In 
another application, So et al. (2007) synthesized and characterized a series of Schiff 
base derivatives, which exhibited liquid crystal properties.  
 
Bis-Schiff bases are produced from two equivalents of aldehyde or ketone 
with a diamine. The bases can be either symmetric or unsymmetric (asymmetric) 
structures, depending on the reacted aldehydes and diamines. Figure 1.2 shows 
examples of symmetric and unsymmetric bis-Schiff bases 1-4 (Lopez et al., 1998a,b). 
Compounds 1 and 2 started off with symmetrical aromatic diamine ring, but the 
aldehyde rings are different. Compound 3 has symmetrical cyclic diamine ring with 
symmetrical aldehyde rings, while both diamine and aldehyde in compound 4 are 
unsymmetric.  
 
Figure 1.2: Some symmetrical and unsymmetrical bis-Schiff bases. 
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Both symmetrical and unsymmetrical bis-Schiff bases are interesting 
compounds particularly when they coordinate around the central metal ion to form 
transition metal ion complexes. For example, the symmetric bis-Schiff base 
complexes are normally used as macrocyclic models, while the unsymmetric 
complexes are used as irregular binding model with peptides (Atkins et al., 1985). 
However, the unsymmetrical compounds are more advanced than their symmetrical 
counterparts in the explaining of the composition and geometry of metal ion binding 
sites in metalloproteins, leading to the enzymatic selectivity of the natural systems 
with synthetic materials (Bu et al., 1997). Intercalation of other derivatives of 
symmetrical bis-Schiff bases with DNA by UV spectroscopy has also been studied 
(Parra et al., 2007). 
 
Various molecular structural studies on bis-Schiff bases and their 
complexes with different metal ions have been reported. Bis-Schiff bases and others 
were found to form suitable inner coordination sphere between tin atom with O and 
N atoms as quadridentate chelates (Teoh et al., 1997). Ruthenium complexes of bis-
Schiff bases derived from o-vanillin and salicyldehyde however, showed dibasic 
tetradentate chelates (Viswanathamurthi et al., 1998). An intramolecular hydrogen 
bond between the O and N atoms in Schiff bases is one of the important factors 
leading to the formation of metal complexes (Cohen et al., 1964). Kabak et al. (2000) 
prepared the derivatives of bis-Schiff bases and studied their photochromic 
conformational properties. The intramolecular hydrogen bond causes a six– 
membered illusory ring to be formed between the O–H group at ortho position of the 
aldehydic moiety and N atom of the aminic moiety (Kawasaki et al., 1999; Fukuda et 
al., 2003); (Figure 1.3).  
CHAPTER ONE                                                                     INTRODUCTION 
4 
 
Figure 1.3: Intramolecular hydrogen bond. 
 
1.2 Benzimidazoles 
Benzimidazole (Figure 1.4) is a heterocyclic compound containing an 
imidazole ring fused at the 4,5-position with benzene ring. Hobrecker prepared the 
first benzimidazole in 1872 when he reduced 2-nitro-4-methylacetanilide, 5 to obtain 
the tautomers 2,5 (or 2,6)-dimethyl benzimidazole (6), (White, 1951; Hofmann, 
1953); (Scheme 1.1).  
 
Figure 1.4: The benzimidazole ring. 
 
 
Scheme 1.1: First benzimidazole 6, prepared by Hobrecker in 1872 (White, 1951). 
 
Since benzimidazoles have similar structures to purines, whose derivatives 
play important roles in biological systems; substituted benzimidazoles also showed 
interesting biological activities. For example, the ring of the benzimidazoles is found 
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as an integral part in the chemical structure of vitamin B12, 7 (Bonnett, 1963; Preston, 
1974); (Figure 1.5).  
 
Figure 1.5: The benzimidazole ring in the chemical structure of vitamin B12, 7. 
 
Many benzimidazoles are pharmaceutical agents and used widely in 
biological system applications (Townsend and Revankav; 1970; Trivedi et al., 2006). 
Some derivatives of benzimidazoles were reported and used as antiviral agents (8-9, 
Gudmundsson et al., 2000; Cheng et al., 2005), topoisomerase I inhibitors (10-11, 
Kim et al., 1996, 1997; Rangarajan et al., 2000; Mekapati and Hansch, 2001) and as 
antiproliferative agent (12, Hong et al., 2004), (Figure 1.6).  
 
Some of 4,5,6,7-tetrahalo-1H-benzimidazoles (13) were synthesised and 
showed antiprotozoal activity against Acanthamoeba castellanii (Kopanska et al., 
2004), antimycobacterial activity against Mycobacterioum strains (14, Kazimierczuk 
et al., 2005). In other studies, they can also act as antibacterial agents (15-16, Ozden 
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et al., 2005; Nezhad et al., 2005), and showed anthelmintic activity against 
Trichinella spiralis (Mavrova et al., 2005), anti-inflammatory and analgesic 
activities (17, Sondhi et al., 2006) and as inhibitors for hepatitis B (Li et al., 2006) 
and C viruses (18, Beaulieu et al., 2004). Some benzimidazoles were also tested as 
anti-HIV (19, Roth et al., 1997; Smith et al., 2003) and anticancer agents (20-21, 
Craigo et al., 1999; Rida et al., 2006). 
 
Figure 1.6: The chemical structures of some benzimidazole derivatives evaluated 
medicinally. 
 
Recent publication also reported the use of phenolic and anisolic ben-
zimidazole derivatives in vasodilator and antihypertensive studies (Soto et al., 2006), 
while other alkyloxyaryl benzimidazole derivatives have been tested for the 
spasmolytic activity (Vazquez et al., 2006). Figure 1.7 shows the chemical structures 
of many useful benzimidazole derivatives evaluated for biological activities. 
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Figure 1.7: Some benzimidazole derivatives evaluated for biological activity. 
 
The preparation of benzimidazole derivatives is well established. 
Monosubstitution occurs mainly at position 2, while the disubstitution at positions 1 
and 2. 
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1.2.1 Substitution at position 2 
1.2.1.1 Reaction of o-arylene diamines with carboxylic acids 
The Philips-type method follows the reaction of o-arylene diamines with 
carboxylic acids or their derivatives using hydrochloric acid or polyphosphoric acid 
(PPA) as a catalyst to produce the respective benzimidazoles 22, (Scheme 1.2). The 
benzimidazoles can also be produced from both reactants at 18 oC for 120 hr at pH 
0.5 (Haley and Maitland, 1951). 
NH2
NH2
HO R
O N
N
H
R
HCl or PPA
22
R = H, CH3, CHCl2, CCl3, CF3, Ph, CH2Ph  
Scheme 1.2: The Phillips-type to prepare the benzimidazole. 
 
In solvent-free conditions with 7-10 mol % 8N HCl as a catalyst, a mixture 
of o-arylene diamines with carboxylic acids or their derivatives reacted in a domestic 
microwave oven at 600 W for 10 min to produce benzimidazoles 23 (Wang et al., 
2007; Scheme 1.3).  
NH2
NH2
R1
HO
O N
N
H
R2
R1
R2MW, HCl
Solvent-free
23
R1 = H, CH3
R2 = H, 2-CH3, 2-Cl, 3-Cl, 4-CH3, 4-Cl, 4-OCH3 
Scheme 1.3: Preparation of benzimidazoles using the method of Wang et al. 
 
1.2.1.2 Reaction of o-arylene diamines with aldehydes 
Kamal et al. (2004) prepared benzimidazoles 24 by reacting o-arylene 
diamines with 4-hydroxybenzaldehydes in ethanolic solution under reflux in the 
presence of Na2S2O5 as oxidizing reagent, while Falco et al. (2006) used the same 
oxidizing reagent to prepared benzimidazoles 25 in dimethylformamide (DMF) 
under reflux for 12 hr, (Scheme 1.4). 
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N
N
CH3
NH2
NH2R
H
O
OH
N
N
H
OH
R
NH2
NH2R1
H
O
R2
N
N
H
R2
R1
R = H,
R1 = H, CH3. R2 = H, F, CH3
Na2S2O5, 
EtOH/H2O
Reflux, 80 
oC 24
Na2S2O5, DMF
120 
oC, 12 hr
25
 
Scheme 1.4: Benzimidazoles preparation in the presence of Na2S2O5. 
 
Other benzimidazole derivatives 26-27 were yielded by refluxing o-arylene 
diamines with benzaldehydes in the presence of NaHSO3 as oxidizing reagent at 140 
oC in N,N-dimethylacetamide (DMA) or in EtOH/H2O at 60 oC, respectively (White 
et al., 2004; Safonov et al., 2006); (Scheme 1.5). 
NH2
NH2
NH2O
H
O
N
N
H
NH2O
H2N NH2
CH3EtO
O
H
O
N
CH3
CH3
CH3
R
R
H
N
N N
H3C CH3
CH3
CH3
OEtO
NaHSO3, DMA
140 oC
26
NaHSO3, EtOH/H2O
60 oC
27
R = H, 3-CH2NMe2, 4-CH2NMe2
 
Scheme 1.5: Benzimidazoles preparation in the presence of NaHSO3. 
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Meanwhile, Bahrami et al. (2008) described a new convenient method for 
the synthesis of benzimidazole derivatives 28 by the reaction of substituted o-arylene 
diamines with aromatic aldehydes in the presence of ceric ammonium nitrate (CAN) 
as a catalytic redox reagent and H2O2 in free solvent for 10-70 min at 50 oC; (Scheme 
1.6). Under microwave irradiation at 1000 W, the reaction between aldehydes and o-
arylene diamines afforded the benzimidazole derivatives 29 (Soto et al., 2006; 
Scheme 1.7). 
NH2
NH2R1
H
O
N
N
H
R1
R2
R2
H2O2 / CAN
solvent-free, 50 oC
28
R1 = H, CH3, NO2
R2 = H, 2-OH, 2-Cl, 3-NO2, 4-CH3, 
         4-OCH3, 4-OH, 4-Cl, 4-F  
Scheme 1.6: Preparation of benzimidazoles using the method of Bahrami et al. 
 
NH2
NH2
R1 H
O
N
N
H
R2
R1
R2
MW
Na2S2O5
29
R1 = H, CH3, NO2, CF3
R2 = 2-OH, 4-OCH3  
Scheme 1.7: The preparation of the benzimidazoles from MW irradiation. 
 
1.2.1.3 Reaction of o-arylene diamines with ketones 
2-Disubstituted benzimidazoline 31 was formed from the reaction between 
o-arylene diamines and ketones by elimination of water, which decomposed under 
heat to produce 2-substituted benzimidazoles, 32-33 and hydrocarbons (Elderfield 
and Kreysa, 1948); (Scheme 1.8). The intermediate 31 was isolated with its tautomer 
30 (Elderfield and Meyer, 1954a,b). 
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R1
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
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H
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NH2
 H2O
NH2
N R2
R1
30
32
R1, R2 = alkyl, aryl33
31
 
Scheme 1.8: Preparation of benzimidazoles using the method of Elderfield and 
Kreysa. 
 
1.2.1.4 Benzimidazole derivatives from -diketone 
Benzimidazole derivatives can also be synthesized from -diketone. This 
was described by Rossi et al. (1960) when o-phenylenediamine was heated with -
diketone derivatives in xylene with acidic media to furnish good yields of 34-35 
(Scheme 1.9). 
 
Scheme 1.9: Benzimidazoles from -diketones. 
 
1.2.1.5 Benzimidazoles from the reaction of o-arylene diamines with 
quinoxalin-2-one derivatives 
Novel benzimidazoles were obtained from the reaction between o-arylene 
diamines and quinoxalin-2-one derivatives under reflux in acetic acid for 2 hr to 
afford 2-benzimidazolylquinoxaline derivatives, 35. Good yield of 35 was obtained, 
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which depends on the position of R in o-phenylenediamine (Mamedov et al., 2008); 
(Scheme 1.10).  
NH2
NH2R2
R1 N
NO
H
O
R3
R3
N
NR3 N
NR3
H
R1
R2
35
R1, R2 = H, CH3, NO2
R3 = H, CH3
AcOH, 2 hr
reflux
 
Scheme 1.10: Preparation of benzimidazoles using the method of Mamedov et al. 
 
1.2.1.6 Benzimidazoles from o-nitroarylamines 
The reaction between o-nitroarylamines and aldehydes forms N-
benzylidene-2-nitroaniline derivatives 36, which was converted to 2-substituted 
benzimidazole derivatives 37 by the reductive cyclization using trialkyl phosphite 
(Smith and Suschitzky, 1961; Scheme 1.11). The trialkyl phosphite which acts as a 
reducing agent reduced the nitro group, followed by intramolecular cyclization 
process to produce 37 (Grimmett, 1997). 
NH2
NO2R
H
O
N
NO2R
H
N
N
H
R
36
R = H, CH3
37
(EtO)3P, t-BuC6H5
reflux
 
Scheme 1.11: Benzimidazoles from o-nitroarylamines. 
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1.2.1.7 Benzimidazoles from o-azidoanilines 
Thermolysis method is used to react o-azidoarylamines with aldehydes to 
produce good yields of N-benzylidene-2-azidoaniline derivatives, 38, which were 
converted to 2-substituted benzimidazole derivatives, 39 (Krbechek and Takimoto, 
1964; Hall and Kamm, 1965). Recently, Shen and Driver (2008) synthesized 
benzimidazoles from o-azidoanilines in two steps; using MgSO4 in dichloromethane 
(DCM) at room temperature for 36 hr, followed by the addition of 30 mol % FeBr2 as 
a catalyst with 4 Å molecular sieves in DCM at 40 oC for 12 hr (Scheme 1.12). 
Ferrous bromide, a Lewis acid was coordinated to the imine nitrogen to increase the 
electronegativity of 38, followed by the reduction to generate 40, which dissociated 
from iron catalyst to produce 41. The tautomerisation of 41 gave 39. 
NH2
N3
H
O
R2
N
N3
H
R2
R1
R1
38
R1 = H, CH3, R2 = NO2, CN, Cl
MgSO4
DCM, 25 oC
 
 
N
N3
H
R2
FeBr2 (30 mol %),
4 Å MS, 40 oCR1
N
N
H
R2
FeBr2
R1
- N2
N
N
H
R2
R1
- FeBr2
R1
R1
R1
N
N
H
R2
N
N
H
R2
FeBr2
N2
N
N
H
R2
FeBr2
N2
3941
40
38
R1 = H, CH3, R2 = NO2, CN, Cl  
Scheme 1.12: Benzimidazoles from o-azidoarylamines. 
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1.2.1.8 Benzimidazoles from amidines 
There are two ways of synthesizing benzimidazole derivatives 42 from 
amidines; i) by the reaction of N-arylamidines with benzenesulfonyl chloride in a 
base under anhydrous conditions (Preston, 1974), ii) by the oxidation of the amidines 
using sodium hypochlorite in basic media via N-chloroamidines 43 (Grenda et al., 
1965); (Scheme 1.13). 
N
OH
R
NH2Cl 

Cl
S
O O
N
H
R
NH2Cl 

N
N
H
R
N
H
R
N
Cl
OH
NaOCl
Py.
NaO
Cl, 
OH
 
42
43
R = C2H5, phenyl
R = C2H5, phenyl
 
Scheme 1.13: Benzimidazoles from amidines. 
 
1.2.1.9 Benzimidazoles from resin-bound esters 
Lim et al. (2008) prepared 2-substituted benzimidazoles 44 from the 
condensation process between o-arylene diamines and resin-bound esters under 
microwave irradiation condition in the presence of PPA and N-Methyl-2-pyrrolidone 
(NMP) at 150 oC for 10 min and then 230 oC for 30 min to give an excellent yield 
(Scheme 1.14). 
O R2
O
R1
N
N
R2
H
NH2
NH2
N
R1
44
15% PPA in NMP
MW,
150 oC, 10 min;
230 oC, 30 min
R1 = H, 4-CH3, 4-F,
R2 =
 
Scheme 1.14: Synthesize benzimidazoles by MW assay using the method of Lim et 
al. 
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1.2.2 1,2-Disubstitution of benzimidazoles 
1.2.2.1 Benzimidazoles from o-arylene amines 
The protection of one of the amino groups in o-arylene amines produced a 
derivative of N-substituted o-arylenediamine 45. A cyclization of 45 with the second 
molecule of aldehyde derivatives in the presence of Na2S2O5 as an oxidizing reagent 
produced the benzimidazole derivative 46 (Ozden et al., 2005); (Scheme 1.15).  
NH2
O
O
H
H
O
R3
NH2
N
H
R1
O
O
R2
N
N
R1
R3
O
O
R2
Na2S2O5
R2OH / HCl
45
R1 = H, n-propyl, benzyl, 2,4-Cl benzyl,
R2 = CH3, CH2CH3,
R3 = COOH, CN.
46
N
H
R1
 
Scheme 1.15: Synthesize benzimidazoles with Na2S2O5 using the method of Ozden 
et al. 
 
Kilcigil et al. (1999, 2003) used oxidative condition by adding NaHSO3 in 
DMF at 110 oC for 4.5 hr to prepare the benzimidazoles 47 from 45 (Scheme 1.16). 
Both 46 and 47 were evaluated as having antimicrobial activity against for Candida 
albicans. The reaction of two moles of aldehyde derivatives with one mole of o-
arylene amine in the presence of a catalytic amount of p-toluenesulfonic acid 
produces 2-arylbenzimidazoline 48, which is converted to alcohols and 2-
arylbenzimidazole derivative 49 by redox process. Benzimidazole derivative 50 is 
generated when 49 is heated in ethanolic solution. The product was then tested as an 
anti-HIV agent (Rao et al., 2002); (Scheme 1.17). 
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NH2
N
H
R1
O
O
R2
N
N
R1
R3
O
O
R2
R3
H
O
R3
R3
1. EtOH / H2O, NaHSO3
2. DMF, 110 oC, 4.5 hr
45
R1 = benzyl,
R2 = CH3,
R3 = H, benzyloxy.
47  
Scheme 1.16: Synthesize benzimidazoles with NaHSO3 using the method of Kilcigil 
et al. 
 
NH2
NH2R2
R1
H
O R3
R4
N
N
R1
R2
R3
R4
R4
R3
H+
H
R1
R2
R3
R4
N
N
N
N
H
R1
R2
R3
R4
H
ArCHO
ArCH2OH
p-toluenesulfonic acid
EtOH, 2 hr
48
R1 = H, CH3, OCH3, benzyl,
R2 = H, CH3, OCH3, CO2H, benzyl,
R3 = F, Cl,
R4 = H, F, Cl.
49
50
 
Scheme 1.17: Synthesize benzimidazoles with p-toluenesulfonic acid using the 
method of Rao et al. 
 
In another method, Perumal et al. (2006) reacted two moles of various 
aldehydes with o-phenylenediamines in the presence of montmorillonite K-10 under 
microwave irradiation and in the absence of solvent to produce bis-Schiff bases 51, 
which is cyclized thermally to benzimidazole derivatives 52; (Scheme 1.18). 
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NH2
NH2
H
O
N
N NN
HH
R
R R
R
R
K-10 clay
MW
52
2
51
R = H, 2-OCH3, 2-Cl, 2-NO2, 4-Cl, 4-CH3, 4-OCH3, 4-NO2  
Scheme 1.18: Benzimidazoles from MW irradiation by K-10 clay. 
 
1.2.2.2 Benzimidazoles from o-haloarylamines 
The amidation of o-haloarylamine to 53 occurred by heating a mixture of 
2-bromoanilines with the amides in the presence of POCl3 in toluene. It was then 
treated with 5–10% Pd(PPh3)4 catalyst mixed with NaOtBu and K2CO3 in toluene for 
18 hr under reflux to yield benzimidazole 54 (Brain and Brunton, 2002); (Scheme 
1.19). 
NH2
Br
N
Br
R3
HN
R2
5-10 % Pd(PPh3)4
K2CO3, NaO
tBu,
Toluene, refl., 18 hr
R1
N
O
R2
H
R3
R1
R1
N
N
R2
R3
POCl3, Et3N
Toluene, 
reflux, 18 hr 53
R1 = H, 3-CH3, 5-OCH3, 5-NO2
R2 = CH3, CH2CH3, benzyl
R3 = CH3, Ph
54
 
Scheme 1.19: Synthesize benzimidazoles with 5-10% Pd(PPh3)4 using the method of 
Brain and Brunton. 
 
1.2.2.3 Benzimidazoles from o-nitroarylamines 
The acetylation of o-nitroarylamines with Ac2O using H2SO4 as catalyst 
produced the acetanilide 55, which was treated with Me2SO4 and KOH to form N-
methylated acetamide 56. Addition of H2SO4, hydrolyzed 56 to N-methyl-2-
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nitroaniline, 57, which was reduced by H2 and Ni-Raney to afford o-
phenylenediamine 58. The benzimidazole 59 was produced by refluxing 58 with 
CF3COOH. Compound 59 showed antiparasitic activity against Giardia intestinalis, 
Trichomonas vaginalis and Plasmodium falciparum (Vazquez et al., 2006); (Scheme 
1.20). 
NO2
NH2
R NO2
N
R
H
O
CH3
NO2
N
R
CH3
O
CH3
N
N
R
CH3
CF3
NH2
N
R
CH3
H
NO2
N
R
CH3
H
H3O
+
monoglyme
Me2SO4, KOH
56
R = F, CF3, CN
55
H2/Ni-Raney
MeOH
57
CF3COOH
HCl, refl.
5859
Ac2O
H2SO4
 
Scheme 1.20: Synthesize benzimidazoles using the method of Vazquez et al. 
 
1.2.2.4 Benzimidazoles from o-halonitrobenzenes 
Many researchers have reported the methods to synthesize benzimidazoles 
62 and 63 starting from o-halonitrobenzene derivatives, which was then aminated to 
produce o-nitroarylamine 60. The reduction of 60 with NiCl2/Zn or with H2 and Pd/C 
afforded o-phenylenediamine derivative 61. The cyclization of 61 with 
corresponding benzaldehydes in the presence of Cu(AcO)2/H2S, or in the presence of 
Na2S2O5 in DMF gave benzimidazoles 62 and 63 (Goker et al., 1998, 2002). 
However, using carboxylic acid derivatives in the presence of N,N,N`,N`-tetramethyl-
O-(7-azabenzotriazole-1-yl) uranium hexafluorophosphate (HATU) as a coupling 
reagent and a base N,N-diisopropylethylamine (DIPEA) or Hunig`s base in DMF 
under acidic condition, afforded benzimidazole 63 (Page et al., 2008; Scheme 1.21). 
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H
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X1 = F, Cl
X2 = Cl, CF3, CN
R1 = H, CH2CH3, benzyl
R2 = H, 2-Cl, 2-F, 3-F, 3-NO2, 4-Cl, 4-F, 4-OCH3
60
NiCl2/Zn
 or H2, Pd/C
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Scheme 1.21: Synthesize benzimidazoles using the method of Goker et al. and Page 
et al. 
 
1.2.3 Synthesis leading to the formation of both Schiff base and 
benzimidazoles 
Smith and Ho (1971) described the reaction of o-phenylenediamine with 
benzaldehyde by oxidative process in their preparation of 2-amino-N-benzylidene 
aniline, 64, N,N`-dibenzal-o-phenylenediamine, 65, 2-phenylbenzimidazole, 66 and 
1-benzyl-2-phenylbenzimidazole, 67 (Scheme 1.22).  
 
Scheme 1.22: Synthesize Schiff bases and benzimidazoles using the method of Smith 
and Ho. 
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Latif et al. (1983) reported in great detail the reaction of some phenolic 
aldehydes with o-phenylenediamine in boiling ethanolic solution, and they isolated 
the intermediates, 68. Bis-Schiff bases 69 and benzimidazoles 70-71 produced from 
the reaction in most cases depended largely on the substituents in the phenyl ring of 
the aldehyde and the solvent used in the reflux process (Scheme 1.23).  
R1
R2
R1
R2
R1
R2
R1
R2
N
H
N
H
NH2
NH2 H
O
N
NH2
N
N
H
N
N
R1
R2
R1
R2
R1
R2
68
69 70 71
R1 = 2-OH, 3-OH, 4-OH
R2 = H, 3-OCH3, 5-Br, 5-Cl  
Scheme 1.23: Synthesize Schiff bases and benzimidazoles using the method of Latif 
et al. 
 
Both methods resulted in the formation of intermediates 64 and 68 from 
the reaction of one molecule of aldehyde derivatives with o-phenylenediamine under 
low temperature. However, the bis-Schiff bases 65 and 69, including the 
benzimidazoles 66, 67, 70 and 71 were formed when 64 or 68 reacted with the 
second molecule of aldehyde derivative under reflux with nitrobenzene or 1-butanol.  
 
Benzimidazole 73 is an analogue of the natural products 72, which were 
synthesized from benzoic acid in multiple steps by Kumar et al. (2002) which 
produced moderate yields. Other benzimidazole derivative 74 was also prepared 
from the condensation of benzoic acid with o-phenylenediamine derivative. The 
natural products 72 were isolated from acetone extract of Streptomyces sp. 517-02 
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(Shibata et al., 1993; Ueki et al., 1993; Ueki and Taniguchi, 1997) and from 
Streptomyces sp. AJ956 (Sato et al., 2001, Figure 1.8). Both 73 and 74 lacked of 
cytotoxity activity against a range of cancer cell lines (Kumar et al., 2002; Huang et 
al., 2006). 
 
Figure 1.8: Benzimidazole derivatives evaluated against cancer cell lines. 
 
1.3 Scope of this work 
In the current project, four types of different structures were targeted. 2-
Benzyloxy-3-methoxy-benzaldehyde or benzyl o-vanillin 75, two of 2-amino-N-
benzylidene benzeneamines 76 and 82, three of bis-Schiff bases 79, 80 and 81 and 
four of benzimidazoles 77, 78, 83 and 84 were synthesized with modified methods 
and characterized by FTIR, HRMS, 1D and 2D NMR spectroscopy and X–ray 
crystallography (Figures 1.9-1.12). 
 
Benzyl o-vanillin 75 was prepared to protect the hydroxyl group of o-
vanillin, which was benzylated using modified preparation method. The comparison 
of the o-vanillin products and its derivative 75 reactions with o-phenylenediamine 
was studied. Both aldehydes o-vanillin and 75 were used to prepare benzimidazole 
derivatives 77, 78, 83 and 84 via amino benzeneamines intermediates 76 and 82, 
respectively.   
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Figure 1.9: Structure of benzyl o-vanillin 75. 
 
 
Figure 1.10: Structures of 2-amino-N-benzylidene benzeneamines 76 and 82. 
 
Bis-Schiff base 79 was also found as a main product from the reaction 
between o-vanillin with o-phenylenediamine, while both bis-Schiff bases 80 and 81 
were prepared from the reaction of o-vanillin with m-phenylenediamine and p-
phenylenediamine, respectively. The benzimidazoles 77, 78, 83 and 84 were 
evaluated as anti-proliferation with MTT assay. 
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Figure 1.11: Structures of bis-Schiff bases 79, 80 and 81. 
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Figure 1.12: Structures of benzimidazoles 77, 78, 83 and 84. 
CHAPTER ONE                                                                     INTRODUCTION 
24 
1.3.1 The objectives  
The objectives of this work are listed as follows: 
(a) To synthesize 2-benzyloxy-3-methoxybenzaldehyde, 75. 
(b) To synthesize both 2-amino-N-benzylidene benzeneamines 76 and 82. 
(c) To synthesize bis-Schiff bases, 79, 80 and 81. 
(d) To synthesize the benzimidazole derivatives, 77, 78, 83 and 84. 
(e) To elucidate the structures of the synthesized compounds using FTIR, 
HRMS, NMR and X–ray crystallography techniques (if applicable). 
(f) To evaluate the benzimidazoles 77, 78, 83 and 84 as anti-proliferation 
with MTT assay. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Chemicals 
The chemicals that were used throughout the project are listed as follows, 
which were used without further purification: 
Acetone (AR grade) Riedel-de Haёn, Germany. 
Acetone-D6 (acetone-d6) contains 0.03 v/v % TMS 
(for NMR spectroscopy) 
 
Sigma-Aldrich, USA. 
Anhydrous Magnesium sulfate  Fluka Chemika, Switzerland. 
Benzyl bromide  Fluka Chemika, Switzerland. 
Chloroform (CHCl3), (AR grade) Riedel-de Haёn, Germany. 
Chloroform-D (CDCl3) contains 0.03 v/v % TMS 
(for NMR spectroscopy) 
 
Sigma-Aldrich, USA. 
Dichloromethane (DCM), (AR grade) Riedel-de Haёn, Germany. 
Dichloromethane-D2 (CD2Cl2) contains 0.03 v/v % 
TMS (for NMR spectroscopy) 
 
Sigma-Aldrich, USA. 
Diethyl ether Riedel-de Haёn, Germany. 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, USA. 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Life technology, UK. 
Ethanol Riedel-de Haёn, Germany. 
HCT–116 ATCC, Rockville, MD, USA.
Heat inactivated fetal calf serum (HIFCS) Sigma-Aldrich, Germany. 
n-Hexane Riedel-de Haёn, Germany. 
2-Hydroxy-3-methoxybenzaldehyde (o-vanillin) Sigma-Aldrich, USA. 
McCoy’s (growth medium) Gibco, Life technology, UK. 
